Abstract:Annexin A1 (ANXA1) is a calcium-binding protein involved in arachidonic acid metabolism and epidermal growth factor receptor tyrosine kinase pathway. ANXA1 has been implicated in early squamous cell carcinogenesis of esophagus and correlates with degree of tumor differentiation. Our goal was to evaluate ANXA1 expression its correlation with different chemoradiation therapy (CRT) sensitivity and determine its prognostic significance in esophageal squamous cell carcinoma (ESCC). Immunohistochemical staining was used to assay the expression of ANXA1 in 60 patients (14 stage II, 6 stage III, and 40 stage IV) who underwent concurrent CRT from August 2007 to June 2011, and the clinical stage was determined according to the International Union against Cancer (UICC) Tumor-node-metastasis (TNM) 2002 classification. ANAX1 expression level was classified as positive (≥5% of tumor cells with cytoplasmic staining), negative (<5% of tumor cells with cytoplasmic staining), or negative; and was correlated with clinicopathologic features and patients' outcomes. The tissues were classified into responders group (completely remission, CR) and non- responders group (stable disease, SD) by endoscopy, according to the WHO Response Evaluation Criteria in Solid Tumors. The total positive expression rates of ANX A1 was 55.0% (33 of 60). Sixty patients were evaluable for response. There were 11 (18.4%) complete remission, 20 (33.3%) partial remission, 20 (33.3%) stable disease, and 9 (15.0%) progression disease. the positive expression rate of ANX A1 in responders was 72.7% (8 of 11), while 45.0% (9 of 20) in non-responders (p > 0.05). The expression of ANX A1 was not significantly correlated with patients’ age, gender, tumor location, tumor differentiation grade, T stage, N stage and clinical TNM stage (p > 0.05). In univariate analysis, overall survival correlated significantly with tumor differentiation grade (p = 0.004), short-term effect (p < 0.001, TNM stage (p = 0.039), Karnofsky performance status (p = 0.001) and ANXA1 expression (p = 0.050). Subgroup analysis for patients with stage IV, Patient with negative ANX A1 (n = 19) had significantly shorter median survival times than those with positive ANXA1 (n = 21) (11.4 months vs 13.1 months, p = 0.039). Our results indicate that positive ANXA1 expression is frequent in esophageal squamous cell carcinoma. The expression of ANX A1 was not associated with chemoradiation therapy sensitivity. However, it maybe serves as a novel prognostic biomarker for ESCC.

Expression of Annexin A5 is Associated with Higher Tumor Stage and Poor Prognosis in Colorectal Adenocarcinomas.

Expression and Significance of Annexin A2 in Patients with Gastric Adenocarcinoma and the Association with E-cadherin.

Prognostic and Diagnostic Significance of Annexin A2 in Colorectal Cancer.

Increased Level of Phosphorylation-Annexin A2 is Associated with Higher Tumor Stage and Poor Prognosis in Colorectal Adenocarcinomas

Expression of annexin A5 in serum and tumor tissue of patients with colon cancer and its clinical significance

Annexin A5 is a novel prognostic biomarker in oral squamous cell carcinoma

Annexin I and Tumor

Annexin A9 promotes invasion and metastasis of colorectal cancer and predicts poor prognosis

Differential Expression of ANXA1 in Benign Human Gastrointestinal Tissues and Cancers

Annexin A9 promotes cell proliferation by regulating the Wnt signaling pathway in colorectal cancer

Nuclear Localization of Annexin A1 Correlates with Advanced Disease and Peritoneal Dissemination in Patients with Gastric Carcinoma

The Negative Expression of Annexin A1 in Esophageal Squamous Cell Carcinoma is Associated with Poor Outcome

Annexin-1 Downregulation is Associated with Clinical Outcome in Chinese Patients with Hilar Cholangiocarcinoma

Association of serum annexin A1 with treatment response and prognosis in patients with esophageal squamous cell carcinoma

Aberrant Expression of SCARA5 in Lung Adenocarcinoma and its Clinical Significance

Annexin A1 Expression Is Associated with Epithelial–Mesenchymal Transition (EMT), Cell Proliferation, Prognosis, and Drug Response in Pancreatic Cancer

Tissue Microarray Analysis Reveals Strong Clinical Evidence for a Close Association Between Loss of Annexin A1 Expression and Nodal Metastasis in Gastric Cancer

Inhibition of Annexin A3 Suppresses Cell Proliferation and Aggressiveness in Colorectal Cancer

Analysis of the Expression and Prognostic Value of Annexin Family Proteins in Bladder Cancer.

Overexpression of Anillin (ANLN) is Correlated with Colorectal Cancer Progression and Poor Prognosis.

Annexin A4 and cancer